1335210-23-5

Basic information

• Product Name: 1-(2,2-diMethoxyethyl)-5-Methoxy-6-(Methoxycarbonyl)-4-oxo-1,4-dihydropyridine-3-carboxylic acid
• Synonyms: Dulotegravir Me-N-4;1-(2,2-Dimethoxyethyl)-1,4-dihydro-3-methoxy-4-oxo-2,5-pyridinedicarboxylic acid 2-methyl ester;1-[2,2-bis(methyloxy)ethyl]-5-(methyloxy)-6-[(methyloxy)carbonyl]-4-oxo-1,4-dihydro-3-pyridinecarboxylic acid;1-(2,2-diMethoxyethyl)-5-Methoxy-6-(Methoxycarbonyl)-4-oxo-1,4-dihydropyridine-3-carboxylic acid;2,5-Pyridinedicarboxylic acid, 1-(2,2-dimethoxyethyl)-1,4-dihydro-3-methoxy-4-oxo-, 2-methyl ester;Dolutegravir Intermediates3;1-(2,2-Dimethoxyethyl)-1,4-dihydro-3-methoxy-4-oxo-2,5-pyridinedicarboxylic acid 2-methyl este;1-(2,2-dimethoxyethyl)-5-methoxy-4-oxo-1,4-dihydropyridine-3,6-dicarboxylic acid-6-methyl ester
• CAS NO: 1335210-23-5
• Molecular Formula: C₁₃H₁₇NO₈
• Molecular Weight: 315.27598
• EINECS: -0
• Product Categories: CMLLYL
• Mol File: 1335210-23-5.mol

Chemical Properties

• Boiling Point: 474.1±45.0 °C(Predicted)
• Appearance: /
• Density: 1.36±0.1 g/cm3(Predicted)
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 5.56±0.40(Predicted)
• CAS DataBase Reference: 1-(2,2-diMethoxyethyl)-5-Methoxy-6-(Methoxycarbonyl)-4-oxo-1,4-dihydropyridine-3-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2,2-diMethoxyethyl)-5-Methoxy-6-(Methoxycarbonyl)-4-oxo-1,4-dihydropyridine-3-carboxylic acid(1335210-23-5)
• EPA Substance Registry System: 1-(2,2-diMethoxyethyl)-5-Methoxy-6-(Methoxycarbonyl)-4-oxo-1,4-dihydropyridine-3-carboxylic acid(1335210-23-5)

Safety Data

• Hazardous Substances Data: 1335210-23-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-(2,2-diMethoxyethyl)-5-Methoxy-6-(Methoxycarbonyl)-4-oxo-1,4-dihydropyridine-3-carboxylic acid is used as a key intermediate in the synthesis of Dolutegravir, a potent HIV integrase inhibitor. Its unique structure and functional groups play a crucial role in the development of this medication, which is designed to combat the replication of the HIV virus in infected cells.
As an intermediate in the synthesis of GSK1265744 (I), this compound contributes to the development of new therapeutic agents that can help manage and treat HIV infections more effectively. The presence of multiple reactive sites on the molecule allows for further chemical modifications and the creation of related compounds with potential applications in medicine and other fields.

Upstream product

• 41051-15-4 4-methoxyacetoacetic acid methylester 
• 553-90-2 Dimethyl oxalate 
• 1335210-26-8 methyl 2-(((2,2-dimethoxyethyl)amino)methylene)-4-methoxy-3-oxobutanoate 
• 127958-23-0 methyl 2-[(dimethylamino)methylene]-4-methoxy-3-oxobutanoate 
• 22483-09-6 2,2-dimethoxyethylamine 

Downstream Products

• 1335210-24-6 (3S,11aR)-3-methyl-6-(methyloxy)-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxylic acid 
• 1051375-10-0 (3S,11aR)-N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide 
• 1335210-25-7 (4R,12aS)-N-(2,4-difluorobenzyl)-7-methoxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1’,2’:4,5]pyrazino[2,1-b]oxazine-9-carboxamide 
• 1051375-10-0 (3S,11aS)-N-(2,4-difluorobenzyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide 
• 1616340-68-1 methyl 5-((2,4-difluorobenzyl)carbamoyl)-1-(2,2-dirnethoxyethyl)-3-methoxy-4-oxo-1,4-dihydropyridine-2-carboxylate 
• 1335210-35-9 (4R,12aS)-N-(2,4-difluorobenzyl)-7-methyloxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido [1',2',:4,5]pyrazino[2,1-b] [1,3]oxazine-9-carboxamide 
• 1051375-16-6 dolutegravir 
• 1335210-34-8 (4R,12aS)-7-methoxy-4-methyl-6,8-dioxo-3,4,6,8, 12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxylic acid 
• 1616339-96-8 (2S,6R)-N-(1-(2,4-difluorophenyl)cyclopropyl)-9-hydroxy-8,10-dioxo-3,4,5,6,8,10,14,14a-octahydro-2H-2,6-methanopyrido[1',2^,:4,5]pyrazino[2,1-b][1,3]oxazocine-11-carboxamide 
• 1616339-95-7 (2S,5R)-N-(1-(2,4-difluorophenyl)cyclopropyl)-8-hydroxy-7,9-dioxo-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepme-10-carboxamide trifluoroacetate 
• 1616342-14-3 C₂₂H₂₁F₂N₃O₆ 

Relevant articles and documents

Preparation of the key dolutegravir intermediate via MgBr2-promoted cyclization

A novel approach for synthesizing the key dolutegravir intermediate is described via MgBr2-promoted intramolecular cyclization. Condensation of commercially available methyl oxalyl chloride and ethyl 3-(N,N-dimethylamino)acrylate afforded the vinylogous amide in an excellent yield. Subsequent substitution by aminoacetaldehyde dimethyl acetal and methyl bromoacetate gave rise to the expected precursor for cyclization, which was promoted by MgBr2 to highly selectively convert into pyridinone diester. The key dolutegravir intermediate was finally prepared by the selective hydrolysis of the corresponding diester via LiOH.

Triazole derivative with tumor cell calcium ion channel and preparation method and application thereof

The invention relates to the technical field of pharmaceutical chemistry synthesis, in particular to a triazole derivative with a tumor cell calcium ion channel and a preparation method and application thereof. By click reaction, benzyl in the structure is changed to 1, 2 and 3 - triazole structures to obtain a novel compound, can inhibit growth of tumor cells by influencing calcium ion channels in tumor cells, and has remarkable application value.

Synthesis method of dolutegravir key intermediate

The invention discloses a synthesis method of an dolutegravir key intermediate, and relates to the field of dolutegravir compounds. The method includes the synthesis of 1-(2,2-dimethoxyethyl)-5-methoxyl-6-methoxycarbonyl-4-oxo-1,4-dihydropyridine-3 carboxylic acid, 4-methoxyl-2-methoxymethylene acetoacetate or 4-methoxyl-2-ethoxymethylene acetoacetate is taken as a raw material to synthesize the target product 1-(2,2-dimethoxyethyl)-5-methoxy-6-methoxycarbonyl-4-oxo-1,4-dihydropyridine-3 carboxylic acid through substitution, cyclization and hydrolysis reaction. The operation of synthesis is simple, the reaction conditions are mild, the cost is low, the product quality is good, the yield is high, the total yield is more than 90%, and the dolutegravir key intermediate is suitable for large-scale industrial production.

CONTINUES FLOW PROCESS FOR THE PREPARATION OF ACTIVE PHARMACEUTICAL INGREDIENTS - POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVES AND INTERMEDIATES THEREOF

The present invention discloses continues flow process for the preparation of polycyclic carbamoyl pyridone derivatives and intermediates thereof. In particular, the present invention discloses a process for the preparation of intermediate. Formule (V).

A kind of improved lu tewei preparation process (by machine translation)

The present invention provides anti-aids drugs lu tewei improved preparation process, and for lu tewei bulk drug process control study of the diastereoisomeric synthetic intermediates 6' and its preparation method. The process for preparing the simple routes, simplified for intermediate purification processing, in addition this invention obtained the diastereoisomeric synthetic intermediates 6' help for lu tewei raw material preparation process of quality research. (by machine translation)

Preparation of Dolutegravir Intermediate Diastereomer

A convenient method was developed to prepare the diastereomer of dolutegravir tricyclic intermediate in the catalysis of EDCI/DMAP in up to 87% yield. Different solvents, temperature, and times were optimized. The synthesized diastereomer 6′ could be used as a standard for the industrial manufacture requirement of dolutegravir active pharmaceutical ingredient.

PROCESS FOR THE PREPARATION OF DOLUTEGRAVIR

Processes for the preparation of dolutegravir and pharmaceutically acceptable salts utilizing alkenylamine are disclosed. Intermediates in those synthetic schemes are also disclosed.

An Efficient and Highly Diastereoselective Synthesis of GSK1265744, a Potent HIV Integrase Inhibitor

A novel synthesis of GSK1265744, a potent HIV integrase inhibitor, is described. The synthesis is highlighted by an efficient construction of the densely functionalized pyridinone core as well as a highly diastereoselective formation of the acyl oxazolidine moiety. The latter exploits the target molecules ability to chelate to Mg2+, a key feature in the integrase inhibitors mechanism of action.

PROCESS FOR PREPARING CARBAMOYLPYRIDONE DERIVATIVES AND INTERMEDIATES

The present invention relates to the preparation of carbamoylpyridone derivatives and intermediates.